BRAF and melanoma: As a new result, we found that among the clinicopathological characteristics of the primary tumor, the Clark level of invasion and the localization of melanoma are significant and independent prognostic factors for both PFS and OS in metastatic patients treated with BRAF and MEK inhibitors.